Evidence map›Paper›PMID 22771382›Full record

ReviewAgeing research reviews2013

Pharmacological lifespan extension of invertebrates.

Mark Lucanic, Gordon J Lithgow, Silvestre Alavez

Abstract readReview
In one paragraph

Review in Ageing research reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Article
  2. International journal of molecular sciences · 2023
    Review
  3. Mitochondrial sulfide promotes life span and health span through distinct mechanisms in developing versus adult treatedProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  4. Review
  5. Article
  6. Bridging the Gap: A Geroscience Primer for Neuroscientists With Potential Collaborative Applications.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Reproductive Aging inFrontiers in cell and developmental biology · 2021
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.The journals of gerontology. Series A, Biological sciences and medical sciences · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mark LucanicBuck Institute for Research on Aging, Novato, CA 94945, USA. mlucanic@buckinstitute.org
Gordon J Lithgow
Silvestre Alavez

Funding

Training in Basic Research on Aging and Age-Related DiseaseT32AG000266 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Lisa M Ellerby · 1998 to 2026
$13.8M
Pharmacology of LIfespan ExtensionR01AG029631 · NIA · BUCK INSTITUTE FOR RESEARCH ON AGING · PI LITHGOW, GORDON J · 2008 to 2018
$5.4M
Lifespan determination and stress response in C. elegansR01AG021069 · NIA · BUCK INSTITUTE FOR RESEARCH ON AGING · PI LITHGOW, GORDON J. · 2002 to 2006
$2.4M
Comparative Biology of p53, Checkpoint and LongevityR01AG022868 · NIA · BUCK INSTITUTE FOR RESEARCH ON AGING · PI LITHGOW, GORDON J. · 2003 to 2007
$1.9M
Checkpoint functions, lifespan determination and neurodegeneration (3 of 11)RL1ES016655 · NIEHS · BUCK INSTITUTE FOR RESEARCH ON AGING · PI LITHGOW, GORDON J · 2007 to 2011
$1.9M
Interdisciplinary Research Consortium in GeroscienceUL1RR024917 · NCRR · BUCK INSTITUTE FOR RESEARCH ON AGING · PI LITHGOW, GORDON J. · 2007 to 2007
$605k
NCRR NIH HHS UL1 RR024917NIA NIH HHS AG029631-01A1NIA NIH HHS AG21069NIA NIH HHS AG22868NIA NIH HHS R01 AG021069NIA NIH HHS R01 AG022868NIA NIH HHS R01 AG029631NIA NIH HHS T32 AG000266NIA NIH HHS T32AG000266NIEHS NIH HHS ES016655NIEHS NIH HHS RL1 ES016655PHS HHS U19AGO231222
6 · The paper itself

Abstract

There is considerable interest in identifying small, drug-like compounds that slow aging in multiple species, particularly in mammals. Such compounds may prove to be useful in treating and retarding age-related disease in humans. Just as invertebrate models have been essential in helping us understand the genetic pathways that control aging, these model organisms are also proving valuable in discovering chemical compounds that influence longevity. The nematode Caenorhabditis elegans has numerous advantages for such studies including its short lifespan and has been exploited by a number of investigators to find compounds that impact aging. Here, we summarize the progress being made in identifying compounds that extend the lifespan of invertebrates, and introduce the challenges we face in translating this research into human therapies.

Indexed as

AgingAnimalsCaenorhabditis elegansCaloric RestrictionHigh-Throughput Screening AssaysHomeostasisHumansInvertebratesLongevityMammalsMiceOxidative StressSignal TransductionSpecies Specificity

Identifiers

PMID22771382
PMCPMC3552093

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.